Cellectis (CLLS) Net Margin (2015 - 2026)

Cellectis (CLLS) recorded quarterly Net Margin of 152.85% in Q1 2026, up 26.15% quarter-over-quarter from 206.97% in Q4 2025, and up 1729.0% on a YoY basis from 8.36% in Q1 2025.

Cellectis (CLLS) Net Margin (2015 - 2026) Analysis & Trends

Cellectis' Net Margin history runs 12 years deep, the most recent figure standing at 152.85% for Q1 2026.

  • In Q1 2026, Net Margin rose 1729.0% year-over-year to 152.85%; the TTM figure through Mar 2026 stood at 82.82% (up 2656.0% YoY), while the FY2025 annual figure was 92.66%, down 1797.0% from the prior year.
  • Net Margin was 152.85% for Q1 2026 at Cellectis, up from 206.97% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 124.62% in Q1 2024 to a low of 21635.97% in Q1 2023.
  • Historically, Net Margin has averaged 4413.7% across 5 years, with a median of 206.97% in 2025.
  • The sharpest annual moves came in 2023 and 2024: Net Margin tumbled 1971939 bps in 2023, then jumped 2176060 bps in 2024.
  • A 5-year view of Net Margin shows it stood at 167.34% in 2022, then slumped by 8725 bps to 14768.55% in 2023, then surged by 100 bps to 28.99% in 2024, then plunged by 814 bps to 206.97% in 2025, then climbed by 26 bps to 152.85% in 2026.
  • The last three Net Margin figures came in at 152.85% (Q1 2026), 206.97% (Q4 2025), and 1.67% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.82%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 34.53%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Cellectis 17.40 Bn 17.21 Bn - -152.85%

Historic Data

Download Data
DateValue
Mar 31, 2026 -152.85%
Dec 31, 2025 -206.97%
Sep 30, 2025 1.67%
Jun 30, 2025 -141.92%
Mar 31, 2025 -170.14%
Dec 31, 2024 28.99%
Sep 30, 2024 -142.32%
Jun 30, 2024 -313.48%
Mar 31, 2024 124.62%
Dec 31, 2023 -14,768.55%
Sep 30, 2023 -11,278.71%
Jun 30, 2023 -6,576.97%
Mar 31, 2023 -21,635.97%
Dec 31, 2022 -167.34%
Sep 30, 2022 -16,266.86%
Jun 30, 2022 -1,449.58%
Mar 31, 2022 -1,916.58%
Dec 31, 2021 -243.59%
Sep 30, 2021 -450.11%
Jun 30, 2021 -357.19%